CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2019--
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced that the company will
host a conference call and live webcast on Tuesday, February 19, 2019 at
8:00 a.m. EST to report its fourth quarter and full year 2018 financial
results and to discuss recent business updates.
The live webcast can be accessed on the investor page of Sage's website
at investor.sagerx.com. The conference call can be accessed by dialing
1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international)
and using the conference ID 6968949. A replay of the webcast will be
available on Sage's website approximately two hours after the completion
of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering CNS disorders. Sage's lead product
candidate, ZULRESSOâ„¢ (brexanolone) injection, has completed Phase 3
clinical development for postpartum depression and a New Drug
Application is currently under review with the U.S. Food and Drug
Administration. Sage is developing a portfolio of novel product
candidates targeting critical CNS receptor systems, including SAGE-217,
which is in Phase 3 development in major depressive disorder and
postpartum depression. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190205005132/en/
Source: Sage Therapeutics
Investor Contact:
Paul Cox
617-299-8377
paul.cox@sagerx.com
Media
Contact:
Maureen L. Suda
585-355-1134
maureen.suda@sagerx.com